Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Covington
Harvard Business School
Citi
Daiichi Sankyo
Chubb
McKesson
McKinsey
Medtronic

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MOEXIPRIL HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Moexipril Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00588302 Moexipril for Primary Biliary Cirrhosis Completed UCB Pharma Phase 2 The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00588302 Moexipril for Primary Biliary Cirrhosis Completed Mayo Clinic Phase 2 The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00834067 Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions Completed Teva Pharmaceuticals USA Phase 1 The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
NCT00835042 Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions Completed Teva Pharmaceuticals USA Phase 1 The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Moexipril Hydrochloride

Condition Name

Condition Name for Moexipril Hydrochloride
Intervention Trials
Healthy 4
Primary Biliary Cirrhosis 1
Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Moexipril Hydrochloride
Intervention Trials
Liver Cirrhosis, Biliary 1
Liver Cirrhosis 1
Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Moexipril Hydrochloride

Trials by Country

Trials by Country for Moexipril Hydrochloride
Location Trials
United States 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Moexipril Hydrochloride
Location Trials
Pennsylvania 2
Texas 2
Missouri 2
Nebraska 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Moexipril Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Moexipril Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Moexipril Hydrochloride
Clinical Trial Phase Trials
Completed 5
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Moexipril Hydrochloride

Sponsor Name

Sponsor Name for Moexipril Hydrochloride
Sponsor Trials
Paddock Laboratories, Inc. 2
Teva Pharmaceuticals USA 2
University of Nebraska 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Moexipril Hydrochloride
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Argus Health
Federal Trade Commission
Cipla
US Department of Justice
Johnson and Johnson
AstraZeneca
Deloitte
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.